Summary of Key Points Core Viewpoint - A total of 776 stocks reported their latest shareholder numbers as of November 30, with 384 stocks showing a decline in shareholder numbers compared to the previous period, indicating a trend of decreasing investor interest in certain companies [1][3]. Group 1: Shareholder Changes - Among the 776 stocks, 20 stocks experienced a decline in shareholder numbers exceeding 10%, with Huaying Agriculture showing the largest drop of 25.80%, bringing its total to 50,981 shareholders [3]. - Haima Automobile followed with a 19.43% decrease in shareholder numbers, totaling 200,890 [3]. - Other notable declines include Hangzhou High-tech (-18.01%), Xinlong Holdings (-18.00%), and Yahua Group (-17.39%) [3]. Group 2: Market Performance - The average decline for concentrated stocks since November 11 was 4.05%, which underperformed compared to the Shanghai Composite Index's decline of 3.55% during the same period [2]. - Despite the overall decline, 37% of concentrated stocks outperformed the market, indicating pockets of resilience among certain stocks [2]. - Stocks like Green Island Wind and Changshan Pharmaceutical saw significant gains, with Green Island Wind increasing by 38.19% since November 11 [2]. Group 3: Industry Concentration - The concentrated stocks are primarily found in the machinery, power equipment, and basic chemicals sectors, with 50, 36, and 36 stocks respectively [3]. - The performance of these sectors reflects varying levels of investor confidence and market dynamics, with some companies within these sectors showing strong performance despite overall declines in shareholder numbers [3].

Quantitative Models and Construction Methods 1. Model Name: Liquidity Impact Coefficient Model - **Model Construction Idea**: This model measures the liquidity impact of index adjustments on individual stocks by calculating the ratio of net fund flows to the stock's recent average daily trading volume[12][13] - **Model Construction Process**: The liquidity impact coefficient for a stock is calculated as follows: $$ impact_{i} = \sum_{k=1}^{N} \frac{\Delta weight_{k,i} \times AUM_{k}}{amt\_avg_{i,20}} $$ - \( \Delta weight_{k,i} \): Estimated weight change of stock \( i \) in index \( k \) - \( AUM_{k} \): Total assets under management of passive products tracking index \( k \) as of the end of November - \( amt\_avg_{i,20} \): Average daily trading volume of stock \( i \) over the past 20 trading days as of the end of November[12][13] - **Model Evaluation**: The model provides a quantitative framework to estimate short-term liquidity shocks caused by index adjustments, but it is subject to data discrepancies and assumptions, which may lead to deviations from actual results[13] --- Model Backtesting Results Liquidity Impact Coefficient Model - **Top 5 Stocks with Highest Positive Impact Coefficients**: - Zhangjiagang Bank (002839 CH): 11.55[15] - Jiangzhong Pharmaceutical (600750 CH): 11.44[15] - Tower Group (002233 CH): 11.04[15] - Jichuan Pharmaceutical (600566 CH): 10.14[15] - Zhengbang Technology (002157 CH): 9.99[15] - **Top 5 Stocks with Highest Negative Impact Coefficients**: - Shenzhen Expressway (600548 CH): -24.95[16] - Vanward Electric (002543 CH): -20.90[16] - Aviation Materials (688563 CH): -14.06[16] - Huaxi Biology (688363 CH): -10.81[16] - Ninghu Expressway (600377 CH): -10.54[16] --- Quantitative Factors and Construction Methods 1. Factor Name: Net Fund Flow Factor - **Factor Construction Idea**: This factor estimates the net fund inflow or outflow for stocks due to index adjustments, based on changes in index weights and the total AUM of passive products tracking the index[9][10] - **Factor Construction Process**: - Outflow Amount: Total AUM of linked products multiplied by the stock's actual weight in the index as of the end of November - Inflow Amount: Total AUM of linked products multiplied by the estimated weight of the stock in the index post-adjustment - Weight estimation is based on free-float market capitalization and index-specific weighting rules, such as dividend yield weighting or market capitalization weighting[9][10] - **Factor Evaluation**: The factor provides a transparent and systematic approach to estimate fund flows, but it is sensitive to assumptions about future index weights and AUM changes[9][10] --- Factor Backtesting Results Net Fund Flow Factor - **Top 5 Stocks with Highest Net Fund Inflows**: - Victory Precision (300476 CH): 112.61 billion CNY[10] - Dongshan Precision (002384 CH): 99.32 billion CNY[10] - Guangqi Technology (002625 CH): 77.81 billion CNY[10] - Sugon Information (603019 CH): 65.44 billion CNY[10] - Top Group (601689 CH): 53.07 billion CNY[10] - **Top 5 Stocks with Highest Net Fund Outflows**: - China Mobile (600941 CH): -40.02 billion CNY[11] - CRRC Corporation (601766 CH): -36.40 billion CNY[11] - Aluminum Corporation of China (601600 CH): -34.29 billion CNY[11] - TCL Zhonghuan (002129 CH): -30.07 billion CNY[11] - Huagong Tech (000988 CH): -27.44 billion CNY[11]

深圳市福田区中心五路 18 号星河中心大厦 19 层 电话：0755-23993388 传真：0755-86186205 邮编：518048 北京国枫（深圳）律师事务所 关于河北常山生化药业股份有限公司 2025 年第一次临时股东会的 法律意见书 国枫律股字[2025]C0141 号 致：河北常山生化药业股份有限公司（贵公司） 北京国枫（深圳）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2025 年第一次临时股东会（以下简称"本次会议"）。 3．本所及经办律师依据《证券法》《证券法律业务管理办法》《证券法律业务执 业规则》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法定 职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见所认 定的事实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导 性陈述或者重大遗漏，并承担相应法律责任； 4．本法律意见书仅供贵公司本次会议之目的使用，不得用作任何其他用途。本所 律师同意将本法律意见书随贵公司本次会议决议一起予以公告。 本所律师根据《中华人民共和国公司法》《证券法》《股东会规则》《证 ...

一、会议召开和出席情况 证券代码：300255 证券简称：常山药业 公告编号：2025-49 河北常山生化药业股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 河北常山生化药业股份有限公司（以下简称"公司"）于 2025 年 11 月 15 日 以公告方式向全体股东发出召开 2025 年第一次临时股东会的通知。本次股东会 采取现场投票和网络投票相结合的方式召开。其中现场会议于 2025 年 12 月 1 日下午 14:30 在中国（河北）自由贸易试验区正定片区正定县高新技术产业开发 区南区梦龙街 71 号河北常山生化药业股份有限公司办公楼会议室召开，本次会 议由董事会召集，董事长高晓东先生主持本次会议；通过深圳证券交易所交易系 统进行网络投票的具体时间为 2025 年 12 月 1 日 9:15—9:25、9:30—11:30、13:00 —15:00；通过深圳证券交易所互联网投票的具体时间为 2025 年 12 月 1 日 9:15 至 15:00 期间的任意时间。 出席本次股东会的股东共 793 名，代表 ...

Market Overview - The chemical pharmaceutical sector increased by 0.16% on December 1, with Changshan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3914.01, up 0.65%, while the Shenzhen Component Index closed at 13146.72, up 1.25% [1] Top Gainers in Chemical Pharmaceutical Sector - Changshan Pharmaceutical (300255) closed at 67.70, up 8.93% with a trading volume of 353,700 shares and a transaction value of 2.379 billion [1] - Laimei Pharmaceutical (300006) closed at 5.42, up 5.24% with a trading volume of 821,100 shares [1] - Oukang Pharmaceutical (920230) closed at 13.22, up 3.44% with a trading volume of 11,400 shares [1] Top Losers in Chemical Pharmaceutical Sector - Yifang Bio (688382) closed at 27.05, down 8.24% with a trading volume of 315,300 shares [2] - Keyuan Pharmaceutical (301281) closed at 27.96, down 4.51% with a trading volume of 44,300 shares [2] - Kangzhiyue Pharmaceutical (300086) closed at 12.17, down 4.32% with a trading volume of 864,700 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 1.011 billion from institutional investors, while retail investors saw a net inflow of 466 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Maiwei Bio (688062) had a net inflow of 48.528 million from institutional investors, but a net outflow of 65.659 million from retail investors [3] - Lijun Group (000513) saw a net inflow of 23.529 million from institutional investors, with a net outflow of 25.007 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 18.642 million from institutional investors, while retail investors experienced a net inflow of 10.459 million [3]

Core Points - Shenzhen Stock Exchange and Shenzhen Securities Information Co., Ltd. will implement periodic adjustments to the sample stocks of various indices, including the Shenzhen Component Index and ChiNext Index, on December 15, 2025 [1] - The Shenzhen Component Index will replace 17 stocks, the ChiNext Index will replace 8 stocks, the Shenzhen 100 will replace 7 stocks, and the ChiNext 50 will replace 5 stocks [1] Group 1: Shenzhen Component Index Adjustments - 17 stocks will be added to the Shenzhen Component Index, including 深深房A (000029.SZ), 拓维信息 (002261.SZ), and 海能达 (002583.SZ) [1][2] - The stocks being removed from the Shenzhen Component Index include 国药一致 (000028), 中国天檐 (000035), and 海德股份 (000567) [2] Group 2: ChiNext Index Adjustments - 8 stocks will be added to the ChiNext Index, including 双林股份 (300100.SZ) and 常山药业 (300255.SZ) [1][3] - The stocks being removed from the ChiNext Index include 富临精工 (300432) and 长盛轴承 (300718) [3] Group 3: Shenzhen 100 and ChiNext 50 Adjustments - The Shenzhen 100 Index will see 7 new additions, including 藏格矿业 (000408) and 国货航 (001391) [1][3] - The ChiNext 50 Index will have 5 stocks replaced, with specific stocks not detailed in the provided information [1]

Core Viewpoint - Changshan Pharmaceutical has attracted attention from Element Fund, which plans to acquire 46 million shares from the company's controlling shareholder at a significant price, despite the company's ongoing losses and high stock price [1][2]. Group 1: Share Transfer Details - The controlling shareholder, Gao Shuhua, will transfer 46 million shares, representing 5.01% of the total share capital, to Element Fund at a price of 46.25 yuan per share, totaling 2.128 billion yuan [2]. - The transfer price is approximately 20% lower than the closing price of 57.3 yuan per share on November 20 [2]. - After the transaction, Gao Shuhua's shareholding will decrease from 30.7% to 25.7% [2]. Group 2: Company Performance and Stock Price - Changshan Pharmaceutical's stock price has surged by 192.25% since the beginning of 2025, and nearly 12 times since the low in September 2023, driven by investor interest in its drug Aibennate [1][3]. - Despite the stock price increase, the company has reported continuous losses since 2023, with a net loss of 1.24 billion yuan in 2023 and 249 million yuan in 2024 [10]. - Revenue has declined significantly, with 2023 revenue at 1.41 billion yuan, down 39.63% year-on-year, and 2024 revenue at 1.031 billion yuan, down 26.92% year-on-year [10]. Group 3: Element Fund's Investment Strategy - Element Fund, established in 2014, has a management scale of 500 million to 1 billion yuan and has previously engaged in significant market transactions [4][5]. - The fund has a history of profitable investments, including a notable transaction with Dongyangguang, where it realized a profit of approximately 244 million yuan [6]. - Element Fund's strategy involves acquiring shares through agreements, often involving substantial amounts [8]. Group 4: Market Sentiment and Future Prospects - Despite the company's stock performance, its financial fundamentals do not align with market enthusiasm, as it heavily relies on heparin products for revenue [10][11]. - The potential success of Aibennate, which has recently received approval for weight loss clinical trials, could improve the company's financial situation, but its profitability is uncertain due to shared ownership with ConjuChem LLC [11].

Core Viewpoint - The announcement of a share transfer by the controlling shareholder of Changshan Pharmaceutical has led to a significant increase in the company's stock price, despite ongoing financial losses. The market's interest is largely driven by the potential of the drug Aibennate, which is associated with the weight-loss drug concept. Group 1: Share Transfer Details - On November 21, Changshan Pharmaceutical announced that its controlling shareholder, Gao Shuhua, plans to transfer 46 million unrestricted circulating shares (5.01% of total shares) to Chongqing Element Private Securities Investment Fund Management Co., Ltd. at a price of 46.25 yuan per share, totaling 2.1275 billion yuan [1] - Following the announcement, the stock price of Changshan Pharmaceutical rose, closing at 58.42 yuan per share on November 24, representing a premium of 26.31% over the transfer price [1] - The reason for the share transfer is Gao Shuhua's personal funding needs, while Element Fund recognizes the company's future development potential and investment value [1] Group 2: Financial Performance - In 2023 and 2024, Changshan Pharmaceutical reported revenues of 1.41 billion yuan and 1.031 billion yuan, respectively, reflecting year-on-year declines of 39.63% and 26.92% [1] - The company incurred net losses attributable to shareholders of 1.24 billion yuan and 249 million yuan for the same periods [1] - For the first three quarters of 2025, the company achieved revenue of 681 million yuan, a further decline of 13.11%, with a net loss of approximately 44.82 million yuan [1] Group 3: Stock Price Surge and Drug Development - Despite continuous financial losses, Changshan Pharmaceutical's stock price has surged over 10 times since September 2023, and more than doubled since the low point in April 2025 [2] - The surge is attributed to the drug Aibennate, which is linked to the weight-loss drug concept and belongs to the GLP-1 drug category, benefiting from the market's interest in weight-loss stocks [2] - Aibennate is a product of Changshan Pharmaceutical's subsidiary, Changshan Kaijiejian, established in partnership with ConjuChem LLC, which had already completed early clinical trials before the joint venture [2] Group 4: Recent Developments - As of June 2025, Aibennate has received approval for clinical trials for weight-loss indications, and Changshan Pharmaceutical is preparing for the trials, including supplier selection [3] - The future success of Aibennate remains uncertain and will require time to determine its market viability [3]

Policy Developments - The National Medical Products Administration (NMPA) has expanded the scope of export certificates for pharmaceuticals, allowing companies to apply for export certificates for drugs produced under GMP, regardless of whether they are approved for sale in China [2] - The validity period for the "Drug Export Sales Certificate" has been extended from 2 years to 3 years, aligning it with the "Export Certificate for EU Raw Materials" [2] - The maximum processing time for export certificates has been set at 20 working days, excluding the time required for technical reviews and on-site inspections [2] Drug and Device Approvals - Heng Rui Medicine has received clinical trial approval notices for multiple drugs, including SHR-9839 and SHR-A2009, and will soon commence clinical trials [4] - Renfu Medicine's application for the marketing authorization of Dexmethylphenidate Capsules has been accepted, targeting ADHD treatment, marking a significant step as no similar products are currently available in China [5] - Baile Tianheng's innovative EGFR×HER3 dual-target ADC drug, iza-bren, has had its marketing application accepted, being the first of its kind to enter Phase III clinical trials [6] Capital Markets - Eli Lilly has become the first healthcare company to reach a market capitalization of $1 trillion, with its stock price increasing by 38% this year, driven by investor optimism regarding its weight-loss drug [8] - Changshan Pharmaceutical's controlling shareholder plans to transfer 5% of its shares to Element Fund at a price of 46.25 yuan per share, totaling 2.1275 billion yuan [9][10] Industry Events - A medical representative was sentenced to eight months in prison for fraudulently altering gene test reports to defraud health insurance, highlighting the increasing scrutiny and regulatory measures in the pharmaceutical industry [12] - Heng Rui Medicine has signed a partnership agreement with the Hong Kong Greater China Cancer Foundation to provide innovative therapies for breast cancer patients in Hong Kong [13] - Baicheng Medicine has entered into an exclusive licensing agreement with Zhongshen Innovation for the innovative drug BIOS-0629 in the Greater China region, with milestone payments of 300 million yuan [14] Public Opinion Alerts - Li Xin, former member of the Party Committee and assistant general manager of China Pharmaceutical Health Industry Co., is under investigation for serious violations of discipline and law [16]

Core Viewpoint - Changshan Pharmaceutical has attracted investment from a private equity fund, marking the second time its controlling shareholder, Gao Shuhua, has reduced his stake through a share transfer agreement in recent years [1][3]. Summary by Sections Share Transfer Details - Gao Shuhua plans to transfer 46 million unrestricted shares, representing 5.0051% of the company's total equity, to Chongqing Element Private Securities Investment Fund Management Co., Ltd. [1] - The transfer price is set at 46.25 CNY per share, totaling 2.1275 billion CNY for the transaction, which reflects a discount compared to the closing price of 56.13 CNY on November 21 [3]. Investment Rationale - Gao Shuhua's decision to reduce his stake is driven by personal funding needs, while Element Fund recognizes the growth potential and investment value of Changshan Pharmaceutical [3]. - Element Fund has committed not to sell its shares for 12 months post-transfer, indicating a long-term investment perspective rather than short-term speculation [3][4]. Company Performance and Market Context - Changshan Pharmaceutical focuses on developing, producing, and selling drugs for cardiovascular diseases and has a new drug application for a GLP-1 long-acting injection for type 2 diabetes under review [3][4]. - The company's stock has surged by 180.79% from January 2 to November 21, with a peak price of 71.71 CNY on November 3, despite a lack of financial performance support [4]. - For the first three quarters of the year, Changshan Pharmaceutical reported a revenue of 681 million CNY, a decrease of 13.11% year-on-year, and a net loss of 44.82 million CNY, a decline of 714.77% [4][5]. Historical Context of Share Transfers - This is not the first time Gao Shuhua has reduced his stake through a share transfer; he previously transferred 53 million shares at a price of 9.2 CNY per share last year, resulting in a significant increase in the transfer price this time, exceeding four times the previous price [5].